Skip to main content

Table 2 Potential cardiovascular benefits of DPP-4 inhibitors[38]

From: Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment

Neutral effect on body weight Improved glycemic control, including PPG reduction
Decreased systolic blood pressure Improved lipid profile
Reduction in C-reactive protein (CRP) Improvement of endothelial dysfunction